Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. 2015; 43(1): 78-81 | DOI: 10.5543/tkda.2015.41763

Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report

Gülten Taçoy1, Atiye Çengel1, Zübeyde Nur Özkurt2, Sedat Türkoğlu1
1Department of Cardiology, Gazi University Faculty of Medicine, Ankara, Turkey
2Department of Oncology, Gazi University Faculty of Medicine, Ankara, Turkey

Pulmonary hypertension (PHT) is a pathological condition determined as an increase in mean pulmonary arterial pressure ≥25 mmHg. Pulmonary arterial hypertension (PAH) is precapillary PHT and a life-threatening disease group which consists of different etiologies with the same pathological and clinical findings, and which is characterized by elevated pulmonary vascular resistance. Dasatinib is a dual Src/Abl kinase inhibitor associated with higher affinity for BCR/ABL kinase than imatinib, and is used in the treatment of chronic myelocytic leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia (ALL). We describe a case with ALL, in whom dasatinib treatment induced PAH, and who recovered with bosentan treatment.

Keywords: Acute lymphoblastic leukemia, dasatinib, hypertension, pulmonary.

How to cite this article
Gülten Taçoy, Atiye Çengel, Zübeyde Nur Özkurt, Sedat Türkoğlu. Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report. Turk Kardiyol Dern Ars. 2015; 43(1): 78-81

Corresponding Author: Gülten Taçoy, Türkiye
© Copyright 2020 Archives of the Turkish Society of Cardiology
LookUs & Online Makale